NCT04246047
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04246047
Title Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 7)
Acronym DREAMM 7
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors GlaxoSmithKline
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | POL | NLD | ITA | ISR | GRC | ESP | BEL | AUS

Facility Status City State Zip Country Details
GSK Investigational Site Yuma Arizona 85364 United States Details
GSK Investigational Site Denver Colorado 80218 United States Details
GSK Investigational Site Kansas City Kansas 66205 United States Details
GSK Investigational Site Fairfield Ohio 45242 United States Details
GSK Investigational Site Tyler Texas 75702 United States Details
GSK Investigational Site Liverpool New South Wales 2170 Australia Details
GSK Investigational Site Wollongong New South Wales 2500 Australia Details
GSK Investigational Site Benowa Queensland 4217 Australia Details
GSK Investigational Site Brussels 1090 Belgium Details
GSK Investigational Site Brussels 1200 Belgium Details
GSK Investigational Site Ghent 9000 Belgium Details
GSK Investigational Site Roeselare 8800 Belgium Details
GSK Investigational Site Beijing 100191 China Details
GSK Investigational Site Jinan 250012 China Details
GSK Investigational Site Shenyang 110001 China Details
GSK Investigational Site Alexandroupoli 68 100 Greece Details
GSK Investigational Site Athens 11528 Greece Details
GSK Investigational Site Thessaloniki 54007 Greece Details
GSK Investigational Site Tel Aviv 64239 Israel Details
GSK Investigational Site Bergamo 24127 Italy Details
GSK Investigational Site Meldola FC 47014 Italy Details
GSK Investigational Site Milan 20133 Italy Details
GSK Investigational Site Siena 53100 Italy Details
GSK Investigational Site Aichi 441-8570 Japan Details
GSK Investigational Site Aichi 467-8602 Japan Details
GSK Investigational Site Aomori 030-8553 Japan Details
GSK Investigational Site Ehime 790-8524 Japan Details
GSK Investigational Site Fukuoka 806-8501 Japan Details
GSK Investigational Site Fukuoka 807-8555 Japan Details
GSK Investigational Site Fukuoka 810-8563 Japan Details
GSK Investigational Site Fukuoka 815-8555 Japan Details
GSK Investigational Site Gifu 503-8502 Japan Details
GSK Investigational Site Gunma 377-0280 Japan Details
GSK Investigational Site Hyōgo 670-8540 Japan Details
GSK Investigational Site Kanagawa 221-0855 Japan Details
GSK Investigational Site Kanagawa 247-8533 Japan Details
GSK Investigational Site Kochi 781-8555 Japan Details
GSK Investigational Site Nagano 392-8510 Japan Details
GSK Investigational Site Okayama 701-1192 Japan Details
GSK Investigational Site Osaka 530-0012 Japan Details
GSK Investigational Site Osaka 545-8586 Japan Details
GSK Investigational Site Shizuoka 411-8777 Japan Details
GSK Investigational Site Dordrecht 3318 AT Netherlands Details
GSK Investigational Site Groningen 9713 GZ Netherlands Details
GSK Investigational Site Chorzów 41-500 Poland Details
GSK Investigational Site Krakow 30510 Poland Details
GSK Investigational Site Lodz 93-513 Poland Details
GSK Investigational Site Lublin 20-081 Poland Details
GSK Investigational Site Lublin 20-090 Poland Details
GSK Investigational Site Nowy Sącz 33-300 Poland Details
GSK Investigational Site Poznan 60-569 Poland Details
GSK Investigational Site Warsaw 02-781 Poland Details
GSK Investigational Site Moscow 125284 Russia Details
GSK Investigational Site Nizhny Novgorod 603126 Russia Details
GSK Investigational Site Novosibirsk 630087 Russia Details
GSK Investigational Site Saint Petersburg 191024 Russia Details
GSK Investigational Site Saint Petersburg 197 089 Russia Details
GSK Investigational Site Saratov 410028 Russia Details
GSK Investigational Site Ufa 450083 Russia Details
GSK Investigational Site Pusan 49241 South Korea Details
GSK Investigational Site Ulsan 44033 South Korea Details
GSK Investigational Site Barcelona 08035 Spain Details
GSK Investigational Site Barcelona 08916 Spain Details
GSK Investigational Site Cáceres 10003 Spain Details
GSK Investigational Site Gijón 33394 Spain Details
GSK Investigational Site L'Hospitalet de Llobrega 08908 Spain Details
GSK Investigational Site Murcia 30008 Spain Details
GSK Investigational Site PamplonaNavarra 31008 Spain Details
GSK Investigational Site Salamanca 37007 Spain Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field